+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Etoposide as an in vitro purging agent for the treatment of acute leukemias and lymphomas in conjunction with autologous bone marrow transplantation



Etoposide as an in vitro purging agent for the treatment of acute leukemias and lymphomas in conjunction with autologous bone marrow transplantation



Experimental Hematology 14(7): 626-635



We examined the effects of various concentrations of etoposide (20-125 microM, 2-h incubation) on normal bone marrow and seven malignant cell lines: HL-60, K562, Namalva, MOLT-3, CEM-7, and the Hodgkin's cell lines L428KS and L428KSA. Tumor cell log-kill was dose dependent and greater than 4 for all cell lines but L428KSA (log-kill, 3.73). Median recovery of CFU-GM after purging with 75, 100, and 125 microM etoposide was 3.6%, 1.3%, and 1% of the controls, respectively. After one week of long-term marrow culture (LTMC), recovery increased 10-20 times/10(5) cells plated, reaching median values of 33.6%, 23.5%, and 20.7% of the controls in samples purged with 75, 100, and 125 microM etoposide, respectively. Flow cytometry for cell-cycle analysis and RNA content, and chromosomal studies of one-week-old LTMC from healthy donors detected no significant abnormalities in purged as compared to control cultures. After 3-4 weeks of LTMC, both control and etoposide-treated cells formed confluent monolayers. Using a panel of seven monoclonal antibodies (S3.13, S16.144, S4.7, S8.6, RIB-19, anti-HLA-DR, and VIL-A1), we investigated the expression of early and late differentiation antigens on LTMC after various culture times (0, 1, 2, 3, and 4 weeks). None of the early antigens S3.13, S16.144, and S8.6 was significantly reduced following etoposide treatment, either in nonadherent cells collected from the supernatant or in the adherent cell population obtained from trypsinized monolayers. Etoposide treatment dose dependently delayed the expression of RIB-19 (a late myeloid antigen) and, to a lesser extent, of S4.7 (an "intermediate" myelomonocytic marker). VIL-A1 expression was not affected by etoposide treatment. We conclude that etoposide purging of bone marrow in the 75-125 microM range spares a sufficient number of functionally intact stem cells to allow adequate in vivo reconstitution following autologous transplantation.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 005393215

Download citation: RISBibTeXText

PMID: 3525202


Related references

Autologous bone marrow transplantation using ex-vivo etoposide purged marrow in patients with poor risk lymphomas and acute leukemias. Blood 82(10 SUPPL 1): 629A, 1993

Autologous bone marrow transplantation in the treatment of acute leukemias and malignant lymphomas. Periodicum Biologorum 92(SUPPL 3): 36, 1990

Combined lectin/monoclonal antibody purging of bone marrow for use in conjunction with autologous bone marrow transplantation in the treatment of multiple myeloma. Methods in Molecular Medicine 9: 351-361, 1998

Autologous bone marrow transplantation with microwave marrow purging in vitro for treatment of acute leukemia of 4 cases. Xi'an Yike Daxue Xuebao 17(1): 53, 1996

Combination of hyperthermia with liquid marrow culture for purging leukemic marrow in vitro and application to autologous bone marrow transplantation in treatment of patients with acute leukemia. Experimental Hematology 22(8): 778, 1994

Etoposide purging of marrow harvested from patients with acute leukemias lymphomas or solid tumors. Areman, E M , H J Deeg And R A Sacher (Ed ) Bone Marrow And Stem Cell Processing: A Manual Of Current Techniques Xxxi+487p F A Davis Co : Philadelphia, Pennsylvania, Usa Illus 250-253, 1992

Heterogeneity among the non-Hodgkin's lymphomas. Implications for autologous bone marrow transplantation with in vitro purging using monoclonal antibodies. Cancer 61(6): 1082-1090, 1988

Granulocyte-macrophage colony-stimulating factor. Treatment of patients with highly malignant lymphomas and acute lymphoblastic leukemias after autologous bone marrow transplantation. Ugeskrift for Laeger 154(52): 3754-3757, 1992

Autologous bone marrow transplantation abmt in acute leukemias and lymphomas pesaro italy experience. Bone Marrow Transplantation 5(SUPPL 2): 99, 1990

Bone marrow purging with etoposide/methylprednisolone in patients undergoing autologous bone marrow transplantation. Progress in Clinical and Biological Research 389: 17-21, 1994

Intensive treatment and autologous bone marrow transplantation in cases of leukemias and lymphomas in relapse. Schweizerische Medizinische Wochenschrift 115(43): 1522-1523, 1985

In vitro purging of bone marrow for autologous marrow transplantation in acute myelogenous leukemia using myeloid-specific monoclonal antibodies. Bone Marrow Transplantation 3(5): 387-392, 1988

In vitro purging with asta z of autologous bone marrow transplantation in acute leukemia and lymphoma. Experimental Hematology 13(SUPPL 17): 44-45, 1985

Autologous bone marrow transplantation in acute leukemia after in vitro purging with alkyl lysophospholipids alp. Journal of Cellular Biochemistry Supplement (14 PART A): 335, 1990

Autologous bone marrow transplantation for acute myeloblastic leukemia in Europe: further evidence of the role of marrow purging by mafosfamide. European Co-operative Group for Bone Marrow Transplantation (EBMT). Leukemia 5(10): 896-904, 1991